We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Celgene Corporation announced the U.S. Food and Drug Administration (FDA) has approved Inrebic (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or ...
Celgene has secured the US Food and Drug Administration (FDA) priority review status for the new drug application (NDA) of fedratinib to treat patients with myelofibrosis.